A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations

PCSK9 is a promising target for the treatment of hyperlipidemia and cardiovascular disease. A Quantitative Systems Pharmacology model of the mechanisms of action of statin and anti-PCSK9 therapies was developed to predict low density lipoprotein (LDL) changes in response to anti-PCSK9 mAb for differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadkar, K, Budha, N, Baruch, A, Davis, J D, Fielder, P, Ramanujan, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260002/
https://www.ncbi.nlm.nih.gov/pubmed/25426564
http://dx.doi.org/10.1038/psp.2014.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260002/
https://www.ncbi.nlm.nih.gov/pubmed/25426564
http://dx.doi.org/10.1038/psp.2014.47

Ejemplares similares